Survey of risk factors contributed to lymphatic metastasis in patients with oral tongue cancer by immunohistochemistry

Journal of Oral Pathology and Medicine

Volumn 40, Issue 2, 2011, Pages 127-134

  Zhang, Zhuang ^a   Pan, Jian ^a   Li, Longjiang ^a   Wang, Zhuomin ^b   Xiao, Wenlin ^c   Li, Ningyi ^c  

^a SICHUAN UNIVERSITY   (China)

^b No 452 Hospital of PLA   (China)

^c QINGDAO UNIVERSITY   (China)

Author keywords

Biomarkers; Immunohistochemistry; Lymphatic metastasis; Oral tongue cancer; Risk factor

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN TYPE 1; COLLAGEN TYPE 4; FIBRONECTIN; GELATINASE A; INTERSTITIAL COLLAGENASE; MONOCLONAL ANTIBODY D2-40; UROKINASE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURGERY; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LOGISTIC REGRESSION ANALYSIS; LYMPH FLOW; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SQUAMOUS CELL CARCINOMA; STAINING; TONGUE CANCER; UPREGULATION;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; COLLAGEN TYPE I; COLLAGEN TYPE IV; FEMALE; FIBRONECTINS; HUMANS; IMMUNOENZYME TECHNIQUES; LOGISTIC MODELS; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; ODDS RATIO; RISK FACTORS; STATISTICS, NONPARAMETRIC; TONGUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 79251539562     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2010.00953.x     Document Type: Article

References (33)

1. Day TA, Davis BK, Gillespie MB, et al. Oral cancer treatment. Curr Treat Options Oncol 2003; 4: 27-41.
2. Leemans CR, Tiwari R, Nauta JJ, et al. Regional lymph node involvement and its significance in the development of distant metastases in head and neck carcinoma. Cancer 1993; 71: 452-6.
3. Greenberg JS, Fowler R, Gomez J, et al. Extent of extracapsular spread: a critical prognosticator in oral tongue cancer. Cancer 2003; 97: 1464-70.
4. Shah JP, Singh B. Keynote comment: why the lack of progress for oral cancer? Lancet Oncol 2006; 7: 356-7.
5. Pepper MS. Lymphangiogenesis and tumor metastasis: myth or reality? Clin Cancer Res 2001; 7: 462-8.
6. Xuan M, Fang YR, Wato M, et al. Immunohistochemical co-localization of lymphatics and blood vessels in oral squamous cell carcinomas. J Oral Pathol Med 2005; 34: 334-9.
7. Franchi A, Gallo O, Massi D, et al. Tumor lymphangiogenesis in head and neck squamous cell carcinoma: a morphometric study with clinical correlations. Cancer 2004; 101: 973-8.
8. Van Der Auwera I, Van Laere SJ, Van Den Eynden GG, et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res 2004; 10: 7965-71.
9. Zhuang Z, Jian P, Longjiang L, et al. Oral cancer cells with different potential of lymphatic metastasis displayed distinct biologic behaviors and gene expression profiles. J Oral Pathol Med 2010; 39: 168-75.
10. Lee KH, Choi EY, Hyun MS, et al. Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target. Clin Exp Metastasis 2008; 25: 89-96.
11. Golubkov VS, Strongin AY. Proteolysis-driven oncogenesis. Cell Cycle 2007; 6: 147-50.
12. Hensen EF, De Herdt MJ, Goeman JJ, et al. Gene-expression of metastasized versus non-metastasized primary head and neck squamous cell carcinomas: a pathway-based analysis. BMC Cancer 2008; 8: 168.
13. Ye H, Yu T, Temam S, et al. Transcriptomic dissection of tongue squamous cell carcinoma. BMC Genomics 2008; 9: 69.
14. Bogusiewicz M, Stryjecka-Zimmer M, Szymanski M, et al. Activity of matrix metalloproteinases-2 and -9 in advanced laryngeal cancer. Otolaryngol Head Neck Surg 2003; 128: 132-6.
15. Sarang Z, Haig Y, Hansson A, et al. Microarray assessment of fibronectin, collagen and integrin expression and the role of fibronectin-collagen coating in the growth of normal, SV40 T-antigen-immortalised and malignant human oral keratinocytes. Altern Lab Anim 2003; 31: 575-85.
16. Bindhu OS, Ramadas K, Sebastian P, et al. High expression levels of nuclear factor kappa B and gelatinases in the tumorigenesis of oral squamous cell carcinoma. Head Neck 2006; 28: 916-25.
17. Piemonte M. [TNM - classification of malignant tumors (VI edition - 2002). Innovations in the classification of head and neck neoplasms]. Acta Otorhinolaryngol Ital 2003; 23: 132-5.
18. Miyahara M, Tanuma J, Sugihara K, et al. Tumor lymphangiogenesis correlates with lymph node metastasis and clinicopathologic parameters in oral squamous cell carcinoma. Cancer 2007; 110: 1287-94.
19. Patel BP, Shah SV, Shukla SN, et al. Clinical significance of MMP-2 and MMP-9 in patients with oral cancer. Head Neck 2007; 29: 564-72.
20. Lukomski M, Lewy-Trenda I, Stasikowska O, et al. [Morphological tumor front grading and matrix metalloproteinases type I expression as a prognostic parameter of the presence of lymph node micrometastases in laryngeal carcinoma]. Otolaryngol Pol 2007; 61: 805-10.
21. Beier UH, Holtmeier C, Weise JB, et al. Fibronectin suppression in head and neck cancers, inflammatory tissues and the molecular mechanisms potentially involved. Int J Oncol 2007; 30: 621-9.
22. Tamamura R, Nagatsuka H, Siar CH, et al. Differential expression of basement membrane collagen-IV alpha1 to alpha6 chains during oral carcinogenesis. Virchows Arch 2006; 449: 358-66.
23. Hornebeck W, Emonard H, Monboisse JC, et al. Matrix-directed regulation of pericellular proteolysis and tumor progression. Semin Cancer Biol 2002; 12: 231-41.
24. Kinsenn H, Sato H, Furukawa M, et al. Modulation of cell growth and matrix metalloproteinase-2 activation of oral squamous cell carcinoma as a function of culture condition with type I collagen. Acta Otolaryngol 2003; 123: 987-93.
25. Urtreger AJ, Aguirre Ghiso JA, Werbajh SE, et al. Involvement of fibronectin in the regulation of urokinase production and binding in murine mammary tumor cells. Int J Cancer 1999; 82: 748-53.
26. Beasley NJ, Prevo R, Banerji S, et al. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res 2002; 62: 1315-20.
27. Audet N, Beasley NJ, Macmillan C, et al. Lymphatic vessel density, nodal metastases, and prognosis in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2005; 131: 1065-70.
28. Kyzas PA, Geleff S, Batistatou A, et al. Evidence for lymphangiogenesis and its prognostic implications in head and neck squamous cell carcinoma. J Pathol 2005; 206: 170-7.
29. Padera TP, Kadambi A, Di Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002; 296: 1883-6.
30. He Y, Rajantie I, Ilmonen M, et al. Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis. Cancer Res 2004; 64: 3737-40.
31. Maza S, Valencia R, Geworski L, et al. Influence of fast lymphatic drainage on metastatic spread in cutaneous malignant melanoma: a prospective feasibility study. Eur J Nucl Med Mol Imaging 2003; 30: 538-44.
32. Bono P, Wasenius VM, Heikkila P, et al. High LYVE-1-positive lymphatic vessel numbers are associated with poor outcome in breast cancer. Clin Cancer Res 2004; 10: 7144-9.
33. Cassella M, Skobe M. Lymphatic vessel activation in cancer. Ann N Y Acad Sci 2002; 979: 120-30.